Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07223151 · ClinicalTrials.gov registry record · NA

A Sensory Strategy to Cut Sugary Beverages in African/American and Latine Adolescents

A NA study of Insulin Resistance and Feeding Behavior, sponsored by Nana Gletsu Miller.

Recruiting
Registry status
NA
Development phase
63
Enrollment target
3
Study locations

NCT07223151: Recruiting NA study of Insulin Resistance and Feeding Behavior, sponsored by Nana Gletsu Miller.

NCT07223151 is a NA study of Insulin Resistance and Feeding Behavior that is actively recruiting participants, run by Nana Gletsu Miller. The registered enrollment target is 63 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07223151, a NA study of Insulin Resistance and Feeding Behavior, is actively recruiting participants, sponsored by Nana Gletsu Miller.

RECRUITING
Registry status
NA
Development phase
63 participants
Enrollment target
3
Study locations

Study Summary

The goal of this clinical trial is to test whether replacing sugary sodas with unsweetened, flavored sparkling waters can reduce added sugar intake and improve health in Black/African American and Latine adolescents with obesity who prefer sweet-tasting beverages. The main questions it aims to answer are: * Does replacing sugary sodas with water change liking for sugary drinks, and water? * Do shifts in liking for sweetness lead to improved diet quality and cardiometabolic health? Researchers will compare replacing sugary sodas with one of three alternative beverages: unsweetened sparkling water, plain water, and beverages with gradually reduced sugar to determine which strategy is most effective. Participants will: * Replace sugary sodas with study drinks for 4 weeks * Complete taste tests to measure their liking for and sensory experience of sweetness over 8-weeks * Provide dietary recalls, body measurements, and blood samples over 8-weeks

Primary Outcome

Our primary outcome is the interaction of time with liking for different sugar concentrations. We expect to observe a significant Time\*Sugar Concentration interaction effect for these liking ratings. We expect the interaction term to show that higher concentrations of sugar had lower liking ratings by weeks 4 and 8 (compared to baseline), but that lower concentrations of sugar had higher liking ratings by weeks 4 and 8. Liking ratings are collected on a scale from -110 to 110, with internal ma

Interventions

  • BEHAVIORAL Unsweetened Sparkling Water Replacement
  • BEHAVIORAL Progressively Reduced Sugar Beverage Replacement
  • BEHAVIORAL Plain Water Replacement

Study Locations (3)

Indiana

  • Indiana University School of Public Health - Bloomington - Bloomington
  • Indiana University Hospital - Indianapolis
  • Purdue University - West Lafayette

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2025-07-25
Est. Completion 2027-06
Phase NA
Nana Gletsu Miller

1 total trials

What NCT07223151 shows while recruiting

NCT07223151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (74% lower).

The record links to 5 conditions, with Insulin Resistance appearing as the primary indexed condition, and to 3 interventions - of which Unsweetened Sparkling Water Replacement is the first listed.

NCT07223151 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT07223151 about?

NCT07223151 is a clinical study titled "A Sensory Strategy to Cut Sugary Beverages in African/American and Latine Adolescents". The goal of this clinical trial is to test whether replacing sugary sodas with unsweetened, flavored sparkling waters can reduce added sugar intake and improve health in Black/African American and Latine adolescents with obesity who prefer sweet-tasting beverages. The main questions it aims to answe...

What is the current status of trial NCT07223151?

This trial is currently recruiting. It is a NA study. The enrollment target is 63 participants. The study started on 2025-07-25. Estimated completion is 2027-06.

What conditions does trial NCT07223151 study?

This clinical trial studies the following conditions: Insulin Resistance, Feeding Behavior, Obesity, Adolescent, Taste Perception, Dietary Sugars.

What interventions are being tested in trial NCT07223151?

The interventions under investigation include: Unsweetened Sparkling Water Replacement (BEHAVIORAL), Progressively Reduced Sugar Beverage Replacement (BEHAVIORAL), Plain Water Replacement (BEHAVIORAL).

Who is sponsoring clinical trial NCT07223151?

This trial is sponsored by Nana Gletsu Miller, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07223151 being conducted?

This trial has 3 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07223151's enrollment target sits among peer trials

63 45th of 120 higher than 76 of 120 other Insulin Resistance trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03383575 · 63 participants · Phase 2

    Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • NCT04870944 · 63 participants · Phase 1

    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • NCT05031897 · 63 participants · Phase 2

    Two Step Haplo With Radiation Conditioning

  • NCT05312671 · 63 participants · Phase 2

    Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07223151, the US trial registry maintained by the National Library of Medicine. NCT07223151 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.